Neopharm

Gangwon, South Korea
Gangwon, South Korea

Time filter

Source Type

Choi G.-H.,Samsung | Kim J.-G.,Neopharm | Kwon S.-T.,Neopharm
Journal of the Korean Society of Food Science and Nutrition | Year: 2011

Over-consumption of alcohol leads to many side-effects such as malnutrition, liver disease, and neuronal disorders and many investigators have tired to identify methods for preventing the side-effects of drinking. In this study, we demonstrated the protective effect of a new food component, SAC-1, containing Hovenia dulcis Thumb and Lonicera caerulea Thumb extract against the side-effects of drinking. We observed that blood alcohol concentration, glutamic oxaloacetate transaminase, lipid peroxidation, and total glutathione level decreased significantly in plasma and liver of mice fed the SAC-1 extract before alcohol intoxication. In particular, SAC-1 had more of a protective effect than that of Hovenia dulcis Thumb extract alone. These results suggest that SAC-1 should further be developed to treat alcohol detoxification and stimulate antioxidative potentials.


Deeken J.F.,Georgetown University | Slack R.,University of Texas M. D. Anderson Cancer Center | Weiss G.J.,Virginia per Cancer Center At Scottsdale Healthcare Tgen | Ramanathan R.K.,Virginia per Cancer Center At Scottsdale Healthcare Tgen | And 8 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2013

Background: Docetaxel is a taxane anticancer drug used in a wide variety of solid tumors. Liposomes are versatile drug carriers that may increase drug solubility, serve as sustained release systems, provide protection from drug degradation and toxicities, and help overcome multidrug resistance. This phase I study was conducted to determine the maximum tolerated dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and clinical response of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Methods: LE-DT was administered using a standard 3 + 3 dose escalation schema with dose levels of 50, 65, 85, 110, and 132 mg/m2 IV on a 3-week cycle. Toxicities were assessed using the NCI-CTCAE version 3.0, and response was assessed using RECIST criteria (version 1.0). PK samples were drawn during cycle 1 and analyzed using a non-compartmental analysis. Results: Twenty-four patients were treated for 1-30 cycles (median = 4). No DLTs were experienced through dose levels of 50, 65, 85, and 110 mg/m2. Two out of two patients experienced grade 4 neutropenia at the 132 mg/m2 dose level. When an additional three patients were treated at the expanded 110 mg/m2 dose level, two experienced grade 4 neutropenia. The 85 mg/m2 dose level was reassessed with an expanded group of three additional patients, and only one of three patients experienced grade 4 neutropenia. The protocol was amended to allow G-CSF during cycle 1, and an additional three patients were treated at 110 mg/m2 with no DLTs experienced. No patient experienced significant neuropathy, even patients treated for 19, 20, and 30 cycles. PK followed a two-compartment elimination pattern; there was no correlation between PK and toxicity. Two patients with thyroid and neuroendocrine cancer had partial responses (PR, 8 %), and one patient with non-small-cell lung cancer had an unconfirmed PR. Eight patients (33 %) had stable disease lasting more than 3 months, for a clinical benefit rate of 41 %. Conclusion: LE-DT was well tolerated with expected toxicities of neutropenia, anemia, and fatigue, but without neuropathy or edema. Clinical benefit (SD + PR) was observed in 41 % of the patients. The recommended phase II dose of LE-DT is 85 mg/m2 without G-CSF or 110 mg/m2 with G-CSF. © 2012 Springer-Verlag Berlin Heidelberg.


Rho J.K.,Asan Institute for Life science | Kim T.W.,University of Ulsan | Choi E.K.,University of Ulsan | Yoon S.-J.,Neopharm | And 5 more authors.
Cancer Research | Year: 2014

In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKI) can occur through a generation of bypass signals such as MET or AXL activation. In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets bothMETand AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed. The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER. The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines. Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs. NPS-1034 was also effective in xenograft mouse models of HCC827/GR. Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line. There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance. In addition, NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement. Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement. © 2014 American Association for Cancer Research.


News Article | November 28, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Adenocarcinoma of the Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma of the Gastroesophageal Junction   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2016 addition with 50 market data tables and 13 figures, spread across 320 pages is available at http://www.reportsnreports.com/reports/764551-adenocarcinoma-of-the-gastroesophageal-junction-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis AB Science SA,AbbVie Inc,Advenchen Laboratories, LLC,Amgen Inc.,ArQule, Inc.,AstraZeneca Plc,Boehringer Ingelheim GmbH,Boston Biomedical, Inc.,Bristol-Myers Squibb Company,Cerulean Pharma, Inc.,Daiichi Sankyo Company, Limited,Dr. Reddy's Laboratories Limited,Eli Lilly and Company,F. Hoffmann-La Roche Ltd.,Ganymed Pharmaceuticals AG,Genentech Inc,Gilead Sciences, Inc.,Hutchison MediPharma LimitedImugene Limited,Mebiopharm Co., Ltd.MedImmune LLC,Merck & Co., Inc.,Merck KGaA,Millennium Pharmaceuticals Inc,Neopharm Ltd.,Novartis AG,Oncobiologics, Inc.,Panacea Biotec Limited,Sanofi Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764551 premium report price at US$2000 for a single user PDF license).


The combined expertise creates a key player in the North American analytical market MONTREAL, QC and BOSTON, MA--(Marketwired - Nov 3, 2016) - Neopharm Labs Inc., a leading Quebec-based full-service pharmaceutical testing laboratory, announces its expansion into the United States this morning with the strategic acquisition of Averica Discovery Services Inc. (Averica), a Contract Research Organization (CRO) based in the Greater Boston area with specialized expertise in early stage contract research and analytical development. The addition of Averica to Neopharm Labs' portfolio provides an opportunity for the organization to expand its geographic reach into the U.S., allowing it to pursue its growth strategy and further increase its range of services into the region. "We are very impressed with the knowledge and scientific track record of Dr. Jeffrey Kiplinger and the entire Averica team. The combination of the companies makes us more competitive and allows us to broaden our service offerings to the life sciences industry. Our clients will directly benefit from the merging of our companies' skills and talents," states Nicolas Fortin, President and General Manager of Neopharm Labs. The highly complementary combination of these two companies is unique. The new entity provides a range of services at every stage of the drug development cycle, from R&D to method development and validation, to stability management, and to commercial testing in chemistry and microbiology. By acquiring Averica's specialized expertise in small molecule analysis and purification, Neopharm is creating a company that will be a leader in the field of analytical services. "Our clients can now take advantage of an expanded range of services," adds Dr. Jeffrey Kiplinger, President and CEO of Averica Discovery, who joins Neopharm's Executive Team as Vice President, Science & Innovation. "With this expansion into the U.S. market, Neopharm Labs will continue building on our combined strengths and capabilities in order to provide the very best services to its customers alike." Averica's Boston area laboratory will continue to provide its current services with plans to expand service offerings and lab space. The location will also serve as the U.S. sales office for Neopharm Labs. About Neopharm Labs Neopharm Labs is an independently owned company headquartered in Blainville, Québec, Canada. It is a full service GMP analytical testing laboratory closely collaborating with pharmaceutical, medical devices, natural health, veterinary, as well as cosmetic clients. Serving the life sciences industry for over 25 years, it offers a unique platform to provide complete portfolio validation and testing to the life sciences industry, including: chemistry, microbiology, sterility, quality control, R&D support, ICH stability studies, method validation and transfers, as well as Quality Assurance and Regulatory Affairs consulting services. Its world-class laboratory is regularly inspected by government agencies such as the U.S. FDA and Health Canada, and has been qualified by several world-renowned life sciences industry leaders. Neopharm holds a Canadian Drug Establishment license since 1995 and possesses narcotics, precursors and controlled substances licenses. Neopharm Labs provides services for Canada, U.S. and Global customers since Canada is a privileged participant to the Global Mutual Recognition Agreements (MRA's). Countries where MRA's are in place will accept Certificates of Analysis (CofA's) emitted by their laboratory for the local commercialization of foreign products. For more information, please visit: www.neopharmlabs.com. About Averica Discovery Services Founded in 2007, Averica Discovery Services is a Massachusetts-based analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification. The company supports chemistry teams by providing material and information required to transition programs from drug discovery to development. With extensive experience in pharmaceutical R&D, it currently offers a variety of chromatography-based services, including method development and qualification, impurity isolation and identification, scalable small molecule purification, and custom assay development. For more information, please visit: www.avericadiscovery.com.

Loading Neopharm collaborators
Loading Neopharm collaborators